Current Report Filing (8-k)
January 20 2016 - 2:08PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): January 13, 2016
ORAMED
PHARMACEUTICALS INC. |
(Exact
name of registrant as specified in its charter) |
DELAWARE |
|
001-35813 |
|
98-0376008 |
(State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
Incorporation) |
|
File
Number) |
|
Identification
No.) |
Hi-Tech
Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel |
|
91390 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
+972-2-566-0001
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM
5.02(d) |
election
of directorS |
On
January 13, 2016, the Board of Directors of Oramed Pharmaceuticals Inc., or the Company, increased the size of the Board of Directors
by one and appointed Ms. Xiaopeng Li as a member of the Company's Board of Directors effective January 13, 2016.
Ms.
Li, age 31, is currently a Director of the Chairman’s Office in Hefei Tianmai Biotechnology Development Co. Ltd, or HTBT,
where she has served as the head of the financing and investment activities since 2013. Ms. Li also has served as Chief Financial
Officer of Hi-Tech Brain Investment Company Limited, an affiliated company of HTBT, since 2015. Prior to that she was a senior
auditor in the Shanghai Branch of Ernst & Young Hua Ming LLP, where she served for four years. Ms. Li holds a Bachelor degree
from the College of Economics, Anhui University, a Master of Accounting degree from Monash University, Australia, and a Master
of Management degree from Central Queensland University, Australia.
Ms.
Li was appointed pursuant to the terms of the Securities Purchase Agreement between the Company and Hefei Tianhui Incubation of
Technologies Co. Ltd., dated November 30, 2015.
The
Company has not yet determined if Ms. Li will serve on any of its Board committees.
As
remuneration for her service as a director, Ms. Li will receive the same fees as the Company's other non-executive directors,
as described in the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2015, or the
Form 10-K. In addition, the Company expects to enter into an indemnification agreement with Ms. Li
on substantially the same terms as the agreements previously entered into between the Company and each of its other
directors and executive officers, the form of which is incorporated by reference as an exhibit to the Form 10-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ORAMED
PHARMACEUTICALS INC. |
|
|
January
20, 2016 |
By: |
/s/ Nadav
Kidron |
|
Name: |
Nadav Kidron |
|
Title: |
President
and CEO |
3
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Sep 2023 to Sep 2024